

Cartilage Oligomeric Matrix Protein: A Biomarker for Diagnostic and Monitoring Osteoarthritis

Zahraa M. A. A. Hamodat

Department of Chemistry, College of Science, Mosul University, Mosul, Iraq

Abstract

Osteoarthritis (OA) is a painful, chronic, and widespread disease. Early treatment for disease is very important to prevent the progression of the disease. Currently, X-ray and clinical history are still the most dependable ways to diagnose OA and estimate the severity of disease. However, the joint damage by OA disease begins before it is diagnosed by radiographic changes. Hence, further practices for early diagnosis are required. Biomarkers and particles that are released into fluids during the disease have received many research interests for early diagnosis of OA. Therefore, in order for the biomarker to be beneficial in diagnosing of OA preradiography, it must have a strong and direct association with the disease. Hence, a good approach to detect and follow-up this disease is cartilage oligomeric matrix protein (COMP). COMP is one of the important biomarkers, which is closely related to the breakdown of the articular cartilage and the loss of function. Many studies have suggested that the COMP level is an indicator of the diagnosis and severity of the disease. In this review article, we highlighted the importance's role of COMP in OA.

Keywords: Cartilage oligomeric matrix protein, joint, osteoarthritis, serum, synovial fluid

INTRODUCTION

Osteoarthritis (OA) is the most common form of joint disease.^[1-3] It can cause pain and disability in the elderly.^[4-7] OA and rheumatoid arthritis (RA) are the most common arthritis.^[1,8] Knee and hip are the most common causes of OA, causing pain and mobility disabilities worldwide.^[9] Late-stage joint replacement is the preferred option for effective treatment to relieve pain and improve quality of life.^[9,10] Approximately 10%–20% of patients do not benefit from this surgical approach, and this aspect is still not understood.^[11,12] The increased prevalence of OA over the past years underscores the importance of preventive strategies or more effective treatment based on the reliable indicators.^[9]

Cartilage oligomeric matrix protein (COMP) has an important role in initiating and progressing with OA.^[13,14] Furthermore, the high level of COMP has a clear impact on the severity of the disease.^[15,16] Therefore, the focus on the importance of COMP in OA increased, especially in knee arthritis patients.

OSTEOARTHRITIS AFFECTED THE SYNOVIAL JOINT

Joint is a place where two bones or more connect.^[17] The end of the bones is covered with cartilage.^[18,19] Each joint is protected

by a capsule, which provides support and protection toward external shocks.^[20] The capsule is lined with the synovial membrane (synovium). It is a type of tissue that secretes the synovial fluid (SF) to soften and nourish the joint tissues.^[21-23] In normal physiological condition, the layer of synovium is thin.^[24]

SF is a biofluid in contact with the synovial membrane and the meniscus.^[25,26] It plays a significant function in the mechanical metabolism of articular cartilage tissue.^[27,28] The major difference between SF and other fluids in the body is that it contains a high amount of hyaluronic acid,^[20,26,29] which is characterized by lubrication.^[30] SF is excreted in small amounts by synovium and occasionally by synovial tendon sheaths.^[26,31] Until large joints, a small drop of SF occurs on the joint surface to the lip on each other.^[32] Therefore, isolation

Address for correspondence: Dr. Zahraa M. A. A. Hamodat, Department of Chemistry, College of Science, Mosul University, Mosul, Iraq. E-mail: zahraahamodat@uomosul.edu.iq

Submitted: 05-Aug-2020

Accepted: 16-Aug-2020

Published: 14-Dec-2020

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Hamodat ZM. Cartilage oligomeric matrix protein: A biomarker for diagnostic and monitoring osteoarthritis. *Med J Babylon* 2020;17:311-7.

Access this article online

Quick Response Code:



Website:
www.medjbabylon.org

DOI:
10.4103/MJBL.MJBL_52_20

and analysis are onerous. The effusion continually illustrates articular syndrome.^[28,29,33] A alteration in the structure and functions of the normal joint has been associated with many forms of arthritis.^[21]

Arthritis means inflammatory of the joint, where *arthr* indicates joint and *itis* indicates inflammation.^[31,34,35] There are many types of arthritis that may affect other body parts, such as the internal organs and skin.^[31,34] The most common prevalent types of arthritis are OA and RA.^[8]

OA is a common of arthritis; its prevalence in both developing and development countries.^[36-39] Thus, in the United States, more than 25 million of population has been diagnosed with OA.^[40-42] Further, about 9.3 million of people aged over 45 years affected with OA, causing a clear cost-effective load and an influence on the quality of life.^[17,43] The incidence of OA disease increases with age.^[44,45] Nearly 80% of the population at the age of 65 are infected with the disease.^[46,47] The women are more infected than men, especially after the age of postmenopausal.^[37,48-50]

Articular cartilage is broken due to the imbalance between the construction and destruction of cartilage cells that may cause weakening of the articular cartilage.^[51] OA is characterized by many signs, namely advanced damage to the articular cartilage, narrowness of the joint area, formation of osteophyte, significant deformities in both the bones under the cartilage, synovial membrane, cartilage purse, tendons, and joint muscle, resulting in loss of joint functions.^[43,44,47,49,52-56]

Unluckily, the risk factors that reason of OA are not completely understood.^[7,57] Nevertheless, there are numerous factors that are supposed to show a role in the incidence and improvement of the disease, such as elderly and female sex.^[17,58,59] In addition, smoking and history of family as it is recognized.^[17] Synovial inflammation might happen in the early period of OA improvement; hence, it comes to be a possible aim for the management of knee OA. Unfortunately, the risk factors for a synovium in the knee OA are not fully understood.^[57]

BIOMARKERS AND THEIR CORRELATION WITH OSTEOARTHRITIS

Currently, X-ray and clinical history are still the most dependable ways to diagnose OA and estimate the severity of disease.^[57,60] However, the destruction of the joint caused with OA begins before it is diagnosed by radiographic changes.^[43] Hence, further practices for early diagnosis are required. Biomarkers and particles that are released into fluids during the turnover the matrix have received many research interests for early diagnosis of OA. There are many biomarkers that can be applied to OA diagnosis, such as catabolic enzymes, cytokines, anti-inflammatory markers, and marks of cartilage and bone metabolism.^[44] Biological factors are classified into one or more of the following totals: disease burden, intervention and investigation activity, prognosis, and diagnosis.^[44] Identifying the sensitive diagnostic method for the purpose

of identifying OA disease before radiographic is important to prevent irreversible articular cartilage damage.^[61] Numerous biomarkers have been recognized in the serum or SF or both for diagnosing preradiographic OA.^[15,43,57,62-68]

Therefore, in order for the biomarker to be useful in diagnosing of OA preradiography, it must have a strong and direct correlation with the disease, as well as a clear change in its level between the patients and the healthy people.^[15,53,69] Hence, a good approach is to detect and follow-up on one of these important biomarkers that have a close relationship with the breakdown of the cartilage joint is COMP.

CARTILAGE OLIGOMERIC MATRIX PROTEIN

Cartilage oligomeric matrix protein (COMP) is a glycoprotein, non collagen homopentameric. also, known thrombospondin-5. Its an extracellular matrix (ECM), has molecular weight 524- kDa.^[70-76] COMP presents major in the cartilage; further, later, it was found in smaller quantities in a variety of tissues, such as tendons, fibroblasts, synovium, ligaments, vascular smooth cells, activated platelets, breast cancer cells, and cardiomyocytes.^[7,9,43,44,67,77,78] When cartilage is damaged, it releases from the cartilage to the SF and thus into the blood circulation.^[77]

Function of cartilage oligomeric matrix protein

Function of COMP is still unclear, but there are suggestions that COMP has an important role in the endochondral ossification and the interaction with collagen fibrils by each C-terminal globule, for the purpose of stabilizing the ECM.^[79,80] Furthermore, COMP has an important role in stimulating the formation of fibril for Type I and II collagen, as well as the acceleration of fibril genesis and binding to aggrecan.^[7,43,44,67,78,81]

Association of cartilage oligomeric matrix protein with osteoarthritis

Table 1 reveals that many studies showed the estimation of COMP level either in the serum, SFs, or both in patients with OA. Previous studies have shown that the level of serum COMP can be used to diagnose and distinguish between OA and healthy people, where the serum COMP level for OA patients was found to be higher than healthy people.^[14,16,44,57] In addition, several studies have found that the high level of COMP has been detected in the serum and SF and that its concentration in the SF is higher than in the serum, which means that the COMP is released from the affected joint.^[16,43] Some studies have indicated that patients who have the most crashing joint have a higher COMP level than patients who have a less crashing joint.^[63,82]

Sharif *et al.*, 1995 in detailed study on patients with knee OA found that high COMP levels have a close relationship with the progression of the disease.^[48,82] Besides, Neidhart *et al.*, 1997 also found that the level of COMP serum is high in patients with OA compared to healthy people^[83] and concluded that the changes in the serum COMP can reflect changes in the cartilage breakdown.^[83]

Table 1: Studies on cartilage oligomeric matrix protein either in serum, synovial fluids, or both, in patients with rheumatoid arthritis

Author	Years	Type of OA	Type of fluid	Outcomes
Sharif <i>et al.</i> ^[82]	1995	KOA	Serum	Sharif <i>et al.</i> , 1995 in detailed studies on patients with KOA found that high COMP levels have a close relationship with the progression of the disease
Neidhart <i>et al.</i> ^[83]	1997	OA	Serum	Also found that the level of COMP serum is high in patients with OA compared to healthy people. And concluded that changes in serum COMP can reflect changes in cartilage breakdown
Conrozier <i>et al.</i> ^[84]	1998	Hip OA	Serum	Observed a high level of serum COMP when predicting the development of hip OA symptoms. And concluded that the level of serum COMP as an indicator of OA and possible benefit in using COMP to determine the risk of rapid progression of hip arthritis disease
Clark <i>et al.</i> ^[15]	1999	KOA, hip OA	Serum	Found that the presence of radiographic KOA and hip OA associated with the high level of serum COMP
Vilím <i>et al.</i> ^[85]	2001	OA	Serum	Revealed correlation between synovitis and level of serum COMP
Jordan <i>et al.</i> ^[86]	2003	OA	Serum	Found an increase in the level of COMP serum
Murphy <i>et al.</i> ^[87]	2002	Chondromalacia patellae	Serum	Found an increase level of serum COMP for patients caused with chondromalacia patellae
Andersson <i>et al.</i> ^[88]	2006	KOA	Serum	Showed that the level of COMP does not change during rest. However, the level of serum COMP increases after of exercise, and then decreases after of rest. And concluded that the level of serum COMP increases in KOA while the serum COMP level is lower during rest
Andersson <i>et al.</i> 2006 ^[89]	2006	KOA	Serum	Showed that there was no difference in the level of serum COMP between 8 and 21 h. However, Anderson <i>et al.</i> showed that there is a significant decrease in the level of serum COMP during the night or bed rest, and that the lowest level of COMP is between 4 and 5 h ^[54]
Bijlsma <i>et al.</i> ^[90]	2011	OA	Serum	Found a rise in the level of COMP for OA patients
Hoch <i>et al.</i> ^[61]	2011	KOA	Serum	Noted that serum COMP level was constantly elevated in patients who radiographically diagnosed with knee OA when compared to controls. And concluded that these results point out serum COMP is raised in patients with KOA and is subtle to KOA disease development
Zivanović <i>et al.</i> ^[55]	2011	OA	Serum	Showed a significant difference in the level of serum COMP between patients who get the presence of joint effusion and patients who do not have no joint effusion. As well as a significant difference between patients who have synovitis and patients who do not have synovitis
Gheita <i>et al.</i> ^[16]	2015	OA	Serum, SF	Showed that the COMP level of OA patients in the synovial fluid is higher than in their serum. And the level of serum COMP for OA patients increases with age and severity. Positive correlation between serum COMP level with each of SF COMP level and the severity of disease. Gheita <i>et al.</i> , concluded that COMP level in serum or SF reveal a degree of joint destruction in OA patients. Further, COMP level has potentially reliable diagnostic markers in early diagnosis of joint damage and can be monitored for predicting rapid treatment starting with early-stage patients and monitoring the response to various therapeutic methods. COMP levels in serum or synovial fluid reflect the severity of disease
Arellano <i>et al.</i> ^[43]	2017	KOA	Serum, SF	Showed that KOA patients have a positive correlation between the level of COMP synovial fluid and the level of COMP serum, age, and sampling daytime, also, the high level of COMP is only in the female synovial fluid of patients. Arellano <i>et al.</i> concluded that these results may propose a promising role for serum and synovial fluid COMP as a measure for primary knee osteoarthritis
Martadiani <i>et al.</i> ^[57]	2017	OA	Serum	Showed that the level of serum COMP for OA patients higher than health about 5.5 times. And concluded that elevated the level of COMP might reveal progression of joint matrix turnover or damage
Zhang ^[91]	2018	KOA	Serum	Found that the high level of COMP in the serum of KOA patients is associated with the incidence of KOA disease, and concluded that patients with a higher level of COMP serum have a greater chance of developing KOA

Contd...

Table 1: Contd...

Author	Years	Type of OA	Type of fluid	Outcomes
Hamodat and Al-Ashou ^[92]	2020	OA	Serum, SF	Shown a higher level of serum COMP for OA patients in compression with level of serum COMP; the COMP level in the synovial fluid of OA patients is also higher than the COMP level in their serum. Furthermore, the high level of COMP is in the synovial fluid of female OA patients; and the level of serum COMP increases with age and severity of the disease. They concluded that the COMP level could be a biomarker of the extent of damage to the cartilage joint, which could be used as a diagnostic tool to determine the degree of the disease as well as monitor the effect of treatment

COMP: Cartilage oligomeric matrix protein, SF: Synovial fluid, OA: Osteoarthritis, KOA: Knee osteoarthritis

Furthermore, another study by Conrozier *et al.*^[84] observed a high level of serum COMP when predicting the development of hip OA symptoms. Conrziier *et al.* concluded that the level of serum COMP as an indicator of OA and possible benefit in using COMP to determine the risk of rapid progression of hip arthritis disease.

In addition, Clark *et al.* found the presence of radiographic knee OA and hip OA associated with the high level of serum COMP.^[15] Moreover, Vilim *et al.* revealed correlation between synovitis and level of serum COMP.^[85] Further, Jordan *et al.*^[86] found an increase in the level of serum COMP for OA patients.

In addition, Murphy *et al.* found increase levels of serum COMP for patients caused with chondromalacia patellae.^[87]

Moreover, Andersson *et al.*, 2006 showed that the level of COMP does not change during rest. However, the level of serum COMP increases after of exercise and then decreases after of rest. They concluded that the level of serum COMP increases in knee OA while the serum COMP level is lower during rest.^[88]

Other study by Andersson *et al.*, 2006 showed that there was no difference in the level of serum COMP between 8 and 21 h. However, Anderson *et al.* showed that there is a significant decrease in the level of serum COMP during night or bed rest and that the lowest level of COMP is between 4 and 5 h.^[89]

In addition, Bijlsma *et al.* also found a rise in the level of COMP.^[90] Further, Hoch *et al.*^[61] noted that serum COMP level was constantly elevated in patients who radiographically diagnosed with knee OA when compared to controls and concluded that these results point out that serum COMP is raised in patients with knee osteoarthritis (KOA) and is subtle to KOA disease development.^[61]

The results of Zivanović *et al.* showed a significant difference in the level of COMP serum between patients who get the presence of joint effusion and patients who do not have no joint effusion, as well as a significant difference between patients who have synovitis and patients who do not have synovitis.^[55]

Moreover, Verma and Dalal have observed that the level of COMP serum in OA patients is higher than the control group. Verma and Dalal's results also showed that the level of serum COMP for patients is associated with a negative correlation

with the duration of the disease and a positive correlation with age. In addition, they observed that the difference of sex has an effect on the level of serum COMP for OA patients. Moreover, they found that males have a higher level of COMP than females and concluded that the level of serum COMP could be used as a diagnostic indicator and its value could measure the risk of progression.^[93]

Besides, Singh *et al.*, 2015 showed that the level of serum COMP for patients in conditions with mild was lower than moderate, and in severe condition, it was higher than moderate. Singh *et al.*^[94] concluded that the value of serum COMP can distinguish between patients and health, as well as the value of COP can reflect the severity of the disease.

In addition, Gheita *et al.*, 2015 also showed that the COMP level of OA patients in the SF is higher than in their serum. The level of serum COMP for OA patients increases with age and severity. Positive correlation between serum COMP level with each of SF COMP level and the severity of disease.

Gheita *et al.*, 2015 concluded that COMP level in the serum or SF reveals a degree of joint destruction in OA patients. Furthermore, COMP level has potentially reliable diagnostic markers in early diagnosis of joint damage and can be monitored for predicting rapid treatment starting with early-stage patients and monitoring the response to various therapeutic methods. COMP levels in the serum or SF reflect the severity of disease.^[16]

Moreover, Arellano *et al.*, 2017 showed that KOA patients have a positive correlation between the levels of COMP SF and the levels of COMP serum, age, and sampling daytime; further, the high level of COMP is only in the female SF of patients. Arellano *et al.* concluded that these results may propose a promising role for serum and SF COMP as a measure for primary knee OA.^[43]

Martadiani *et al.*, 2017 showed that the level of serum COMP for OA patients higher than health about 5.5 times and concluded that elevated the level of COMP might reveal progression of joint matrix turnover or damage.^[57]

Zhang, 2018 also found that the high level of COMP in the serum of OA patients is associated with the incidence of KOA disease and concluded that patients with a higher level of COMP serum have a greater chance of developing KOA.^[91]

Hamodat and AL-Ashou^[92] showed a higher level of serum COMP for OA patients in compression with the level of serum COMP; the COMP level in the SF of OA patients is also higher than the COMP level in their serum. Furthermore, the high level of COMP is in the SF of female OA patients, and the level of serum COMP increases with age and severity of the disease. They concluded that the COMP level could be a biomarker of the extent of damage to the cartilage joint, which could be used as a diagnostic tool to determine the degree of the disease as well as monitor the effect of treatment.^[92]

Differences in findings could be the majority of these studies performed with a size sample and did not detail the patient's appearance and medication. However, despite many studies, it remains unclear whether the COMP level is sufficient to diagnose OA patients?

CONCLUSION

Through our reviewer, we could draw a conclusion; it was possible to say that COMP could be considered as a biomarker for the diagnosis and monitoring of OA patients. Further, it is possible to adopt the COMP level as a diagnostic biomarker preradiography as well as possible to adopt the level of COMP as indication of the diagnosis of the severity of the disease.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Bay-Jensen AC, Thudium CS, Mobasheri A. Development and use of biochemical markers in osteoarthritis: Current update. *Curr Opin Rheumatol* 2018;30:121-8.
- Wang X, Cicuttini F, Jin X, Wluka AE, Han W, Zhu Z, *et al.* Knee effusion-synovitis volume measurement and effects of Vitamin D supplementation in patients with knee osteoarthritis. *Osteoarthritis Cartilage* 2017;25:1304-12.
- Tiulpin A, Thevenot J, Rahtu E, Lehenkari P, Saarakkala S. automatic knee osteoarthritis diagnosis from plain radiographs: A deep learning-based approach. *Sci Rep* 2018;8:1727.
- Arden NK, Cro S, Sheard S, Doré CJ, Bara A, Tebbis SA, *et al.* The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: A randomised controlled trial. *Osteoarthritis Cartilage* 2016;24:1858-66.
- Hussain SM, Daly RM, Wang Y, Shaw JE, Magliano DJ, Graves S, *et al.* Association between serum concentration of 25-hydroxyvitamin D and the risk of hip arthroplasty for osteoarthritis: Result from a prospective cohort study. *Osteoarthritis Cartilage* 2015;23:2134-40.
- Inchai C, Mahakkanukrauh P. Biological Markers Associated Osteoarthritis. Vol. 12. Kuala Lumpur: Medical and Health; 2017. p. 18-26.
- Vaishya R, Vijay V, Hussaini SM, Agarwal AK. Association of Vitamin D and knee osteoarthritis—A review. *Apollo Med* 2017;14:3-7.
- Fiador F, Poyade M, Bennett L. The use of augmented reality to raise awareness of the differences between osteoarthritis and rheumatoid arthritis. *Adv Exp Med Biol* 2020;1262:115-47.
- Riegger J, Rehm M, Büchele G, Brenner H, Günther KP, Rothenbacher D, *et al.* Serum cartilage oligomeric matrix protein in late-stage osteoarthritis: Association with clinical features, renal function, and cardiovascular biomarkers. *J Clin Med* 2020;9:268-84.
- Konopka JF, Lee YY, Su EP, McLawhorn AS. Quality-adjusted life years after hip and knee arthroplasty: Health-related quality of life after 12,782 joint replacements. *JB JS Open Access* 2018;3:e0007.
- Dumenci L, Perera RA, Keefe FJ, Ang DC, Slover J, Jensen MP, *et al.* Model-based pain and function outcome trajectory types for patients undergoing knee arthroplasty: A secondary analysis from a randomized clinical trial. *Osteoarthritis Cartilage* 2019;27:878-84.
- Hamilton D, Henderson GR, Gaston P, MacDonald D, Howie C, Simpson AH. Comparative outcomes of total hip and knee arthroplasty: A prospective cohort study. *Postgrad Med J* 2012;88:627-31.
- Watt FE. Osteoarthritis biomarkers: Year in review. *Osteoarthritis Cartilage* 2018;26:312-8.
- Hao HQ, Zhang JF, He QQ, Wang Z. Cartilage oligomeric matrix protein, C-terminal cross-linking telopeptide of type II collagen, and matrix metalloproteinase-3 as biomarkers for knee and hip osteoarthritis (OA) diagnosis: A systematic review and meta-analysis. *Osteoarthritis Cartilage* 2019;27:726-36.
- Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, *et al.* Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: The Johnston County Osteoarthritis Project. *Arthritis Rheum* 1999;42:2356-64.
- Gheita T, El-Awar A, El-Ansary M, Raslan H, El-Defrawy A. Cartilage oligomeric matrix protein (COMP) levels in serum and synovial fluid in osteoarthritis (OA) patients: Correlation with clinical, radiological and laboratory parameters. *Osteoarthritis Cartilage* 2015;23:A85.
- Cibrián Uhalte E, Wilkinson JM, Southam L, Zeggini E. Pathways to understanding the genomic aetiology of osteoarthritis. *Hum Mol Genet* 2017;26:R193-R201.
- Zhu J, Arsovska B, Kozovska K. Acupuncture treatment in osteoarthritis. *Int J Recent Sci Res* 2020;11:37471-2.
- Furmann D, Nečas D, Rebenda D, Čípek P, Vrbka M, Křupka I, *et al.* The effect of synovial fluid composition, speed and load on frictional behaviour of articular cartilage. *Materials (Basel)* 2020;13:1334.
- Singh N. Synovial joints and lubrication mechanisms. *Int J Comput Appl Math* 2017;12:29-33.
- Gladman D, Rahman P, Kellys Textbook of Rheumatology. 52 (2005) 17461755.52 (2005) 17461755.
- Tedesco A, D'Agostino D, Soriente I, Amato P, Piccoli R, Sabatini P. A new strategy for the early diagnosis of rheumatoid arthritis: A combined approach. *Autoimmun Rev* 2009;8:233-7.
- Ashibe Y. Method of Constructing a Normal Joint Structure of a Superconducting Cable. Google Patents; 2011.
- Blewis ME, Nugent-Derfus GE, Schmidt TA, Schumacher BL, Sah RL. A model of synovial fluid lubricant composition in normal and injured joints. *Eur Cell Mater* 2007;13:26-39.
- Hamoudatt ZM, Mustafa LA, AL-Hasani SM. Study of latent matrix metalloproteinase-1 activity in serum and synovial fluid of patients with rheumatoid arthritis. *Raf J Sci* 2014;25:31-9.
- Hammodat ZM, Mustafa LA. Biochemical studies on synovial fluid and serum from rheumatoid arthritis patients. *Raf J Sci* 2018;27:37-46.
- Rinaudo M, Rozand Y, Mathieu P, Conrozier T. Role of different pre-treatments on composition and rheology of synovial fluids. *Polymers* 2009;1:16-34.
- Briere LA, Brandt JM, Medley J. Measurement of protein denaturation in human synovial fluid and its analogs using differential scanning calorimetry. *J Therm Anal Calorim* 2010;102:99-106.
- Kokebie R, Aggarwal R, Lidder S, Hakimiyan AA, Rueger DC, Block JA, *et al.* The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. *Arthritis Res Ther* 2011;13:R50.
- Veselack T, Aldebert G, Trunfio-Sfarghiu AM, Schmid TM, Laurent MP, Wimmer MA. Phospholipid Vesicles in Media for Tribological Studies against Live Cartilage. *Lubricants* 2018;6:19-34.
- Echevaria W, Guzman D, Ocasio Y. Biofluid Dynamics of the Arthritis and Human Body Pain; 2004.
- Song HY, Kim MY, Kim KH, Lee IH, Shin SH, Lee JS, *et al.* Synovial fluid of patients with rheumatoid arthritis induces α -smooth muscle actin in human adipose tissue-derived mesenchymal stem cells through a TGF- β 1-dependent mechanism. *Exp Mol Med* 2010;42:565-73.
- Frisbie DD, Al-Sobayil F, Billingham RC, Kawcak CE, McIlwraith CW. Changes in synovial fluid and serum biomarkers with exercise and early

- osteoarthritis in horses. *Osteoarthritis Cartilage* 2008;16:1196-204.
34. Jambale T, Halyal S. Study of serum calcium/phosphorus in rheumatoid arthritis patients. *Int J Clin Biochem Res* 2017;4:103-5.
35. Frisbie D, Al-Sobayil F, Billingham R, Kawcak C, McIlwraith C. Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses. *Osteoarthritis & Cartilage* 2008;16:1196-204.
36. Mermerci Başkan B, Yurdakul FG, Aydın E, Sivas F, Bodur H. Effect of vitamin D levels on radiographic knee osteoarthritis and functional status. *Turk J Phys Med Rehabil* 2018;64:1-7.
37. Kaur R, Ghosh A, Singh A. Prevalence of knee osteoarthritis and its determinants in 30-60 years old women of Gurdaspur, Punjab. *Int J Med Sci Public Health* 2018;7:825-31.
38. Mahmoud GA, Moghazy A, Fathy S, Niaz MH. Osteoarthritis knee hip quality of life questionnaire assessment in Egyptian primary knee osteoarthritis patients: Relation to clinical and radiographic parameters. *Egypt Rheumatol* 2019;41:65-9.
39. Radwan A, Borai A. Neuropathic pain in Egyptian patients with primary knee osteoarthritis: Relationship with functional status and radiological severity. *Egypt Rheumatol* 2019;41:261-4.
40. Lespasio MJ, Sultan AA, Piuze NS, Khlopas A, Husni ME, Muschler GF, *et al.* Hip Osteoarthritis: A primer. *Perm J* 2018;22:17-84.
41. Munjal A, Bapat S, Hubbard D, Hunter M, Kolhe R, Fulzele S. Advances in molecular biomarker for early diagnosis of osteoarthritis. *Biomol Concepts* 2019;10:111-9.
42. Bowman S, Awad ME, Hamrick MW, Hunter M, Fulzele S. Recent advances in hyaluronic acid based therapy for osteoarthritis. *Clin Transl Med* 2018;7:6.
43. Arellano RD, Aguilar LS, Argüello R, Hernadez F, Gonzalez FF, Moran J. Cartilage oligomeric matrix protein levels in synovial fluid in patients with primary knee osteoarthritis and healthy controls: A preliminary comparative analysis with serum cartilage oligomeric matrix protein. *Arch Rheumatol* 2017;32:189-96.
44. Bi X. Correlation of serum cartilage oligomeric matrix protein with knee osteoarthritis diagnosis: A meta-analysis. *J Orthop Surg Res* 2018;13:262.
45. El-Najjar AR, Ezzeldin N, Khalil SS, El-Gerby KM, Alazizi NM, Ibraheem HA. Vascular endothelial growth factor and colour doppler ultrasonography in knee osteoarthritis: Relation to pain and physical function. *Egypt Rheumatol* 2019;41:139-43.
46. Karsdal MA, Michaelis M, Ladel C, Siebuhr AS, Bihlet AR, Andersen JR, *et al.* Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: Lessons learned from failures and opportunities for the future. *Osteoarthritis Cartilage* 2016;24:2013-21.
47. Ourradi K, Sharif M. Biomarkers for diagnosis of osteoarthritis. *JSM Bone Joint Dis* 2017;1:1002.
48. Nur H, Tuncer T. The relationship between body composition and knee osteoarthritis in postmenopausal women. *Turk J Phys Med Rehabil* 2018;64:121-5.
49. Sankar WN, Nevitt M, Parvizi J, Felson DT, Agricola R, Leunig M. Femoroacetabular impingement: Defining the condition and its role in the pathophysiology of osteoarthritis. *J Am Acad Orthop Surg* 2013;21 Suppl 1:S7-S15.
50. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. *Nat Rev Rheumatol* 2010;6:625-35.
51. Garfinkel RJ, Dilisio MF, Agrawal DK. Vitamin D and its effects on articular cartilage and osteoarthritis. *Orthop J Sports Med* 2017;5:2325967117711376.
52. Lockwood SM, Bannister K, Dickenson AH. An investigation into the noradrenergic and serotonergic contributions of diffuse noxious inhibitory controls in a monoiodoacetate model of osteoarthritis. *J Neurophysiol* 2019;121:96-104.
53. Otterness IG, Swindell AC, Zimmerer RO, Poole AR, Ionescu M, Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: Segregation of the markers into clusters and distinguishing osteoarthritis at baseline. *Osteoarthritis Cartilage* 2000;8:180-5.
54. Yan JY, Tian FM, Wang WY, Cheng Y, Song HP, Zhang YZ, *et al.* Parathyroid hormone (1-34) prevents cartilage degradation and preserves subchondral bone micro-architecture in guinea pigs with spontaneous osteoarthritis. *Osteoarthritis Cartilage* 2014;22:1869-77.
55. Zivanović S, Rackov LP, Zivanović A, Jevtić M, Nikolić S, Kocić S. Cartilage oligomeric matrix protein-Inflammation biomarker in knee osteoarthritis. *Bosn J Basic Med Sci* 2011;11:27-32.
56. Liao W, Li Z, Li T, Zhang Q, Zhang H, Wang X. Proteomic analysis of synovial fluid in osteoarthritis using SWATH-mass spectrometry. *Mol Med Rep* 2018;17:2827-36.
57. Martadiani ED, Kawiya IK, Priya TK, Putra TR, Widiana GR, Djelantik AA, *et al.* High level of serum cartilage oligomeric matrix protein and plasma interleukin-6 increase the risk of ultrasound-detected synovial inflammation in knee osteoarthritis. *Bali Med Journal* 2017;6:23-30.
58. Mabey T, Honsawek S. Role of Vitamin D in osteoarthritis: Molecular, cellular, and clinical perspectives. *Int J Endocrinol* 2015;2015:383918.
59. Sur D, Chakravorty R. Relationship of thyroid and sex hormones with osteoarthritis in postmenopausal indian women. *J Clin Gynecol Obstet* 2017;5:117-20.
60. Karim Z, Wakefield RJ, Quinn M, Conaghan PG, Brown AK, Veale DJ, *et al.* Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: A comparison with arthroscopy and clinical examination. *Arthritis Rheum* 2004;50:387-94.
61. Hoch JM, Mattacola CG, Medina McKeon JM, Howard JS, Lattermann C. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: A systematic review and meta-analysis. *Osteoarthritis Cartilage* 2011;19:1396-404.
62. Cibere J, Zhang H, Garner P, Poole AR, Lobanok T, Saxne T, *et al.* Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. *Arthritis Rheum* 2009;60:1372-80.
63. Fernandes F, Pucinelli ML, da Silva N, Feldman D. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: Clinical and radiological correlation. *Scand J Rheumatol* 2007;36:211-5.
64. Hamoudatt ZM. Isolation of latent matrix metallo proteinase-1 (latent collagenase-1) from serum and synovial fluid of rheumatoid arthritis patient. *Raf J Sci* 2013;24:23-36.
65. Pavelka K, Forejtová S, Olejárová M, Gatterová J, Senolt L, Spacek P, *et al.* Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. *Osteoarthritis Cartilage* 2004;12:277-83.
66. Senolt L, Braun M, Olejárová M, Forejtová S, Gatterová J, Pavelka K. Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. *Ann Rheum Dis* 2005;64:886-90.
67. Tseng S, Reddi AH, Di Cesare PE. Cartilage oligomeric matrix protein (COMP): A biomarker of arthritis. *Biomark Insights* 2009;4:33-44.
68. Wakitani S, Nawata M, Kawaguchi A, Okabe T, Takaoka K, Tsuchiya T, *et al.* Serum keratan sulfate is a promising marker of early articular cartilage breakdown. *Rheumatology (Oxford)* 2007;46:1652-6.
69. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, *et al.* Classification of osteoarthritis biomarkers: A proposed approach. *Osteoarthritis Cartilage* 2006;14:723-7.
70. Di Cesare PE, Carlson CS, Stollerman ES, Chen FS, Leslie M, Perris R. Expression of cartilage oligomeric matrix protein by human synovium. *FEBS Lett* 1997;412:249-52.
71. Englund E, Bartoschek M, Reitsma B, Jacobsson L, Escudero-Esparza A, Orimo A, *et al.* Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer. *Oncogene* 2016;35:5585-96.
72. Fife RS, Brandt KD. Identification of a high-molecular-weight (>400 000) protein in hyaline cartilage. *BBA-Gen Subj* 1984;802:506-14.
73. Hassan WA, Mansour AI. Increased serum and synovial levels of midkine are associated with radiological progression in primary knee osteoarthritis patients. *Egypt Rheumatol* 2019;41:189-95.
74. Huang Y, Xia J, Zheng J, Geng B, Liu P, Yu F, *et al.* Deficiency of cartilage oligomeric matrix protein causes dilated cardiomyopathy. *Basic Res Cardiol* 2013;108:374.
75. Riessen R, Fenchel M, Chen H, Axel DI, Karsch KR, Lawler J. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 2001;21:47-54.
76. Liang Y, Fu Y, Qi R, Wang M, Yang N, He L, *et al.* Cartilage oligomeric matrix protein is a natural inhibitor of thrombin. *Blood* 2015;126:905-14.

77. Felson DT. The current and future status of biomarkers in osteoarthritis. *J Rheumatol* 2014;41:834-6.
78. Posey KL, Coustry F, Hecht JT. Cartilage oligomeric matrix protein: COMPopathies and beyond. *Matrix Biol* 2018;71-72:161-73.
79. Burger A, Roosenboom J, Hossain M, Weinberg SM, Hecht JT, Posey KL. Mutant COMP shapes growth and development of skull and facial structures in mice and humans. *Mol Genet Genomic Med* 2020;8:e1251.
80. Posey KL, Coustry F, Veerisetty AC, Hossain MG, Gambello MJ, Hecht JT. Novel mTORC1 mechanism suggests therapeutic targets for COMPopathies. *Am J Pathol* 2019;189:132-46.
81. Posey KL, Hecht JT. Novel therapeutic interventions for pseudoachondroplasia. *Bone* 2017;102:60-8.
82. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegård D, *et al.* Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. *Br J Rheumatol* 1995;34:306-10.
83. Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA, Häuselmann HJ. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. *Br J Rheumatol* 1997;36:1151-60.
84. Conrozier T, Saxne T, Fan CS, Mathieu P, Tron AM, Heinegård D, *et al.* Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: A one year prospective study. *Ann Rheum Dis* 1998;57:527-32.
85. Vilim V, Vytásek R, Olejárová M, Macháček S, Gatterová J, Procházka B, *et al.* Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. *Osteoarthritis Cartilage* 2001;9:612-8.
86. Jordan JM, Luta G, Stabler T, Renner JB, Dragomir AD, Vilim V, *et al.* Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: The Johnston County Osteoarthritis Project. *Arthritis Rheum* 2003;48:675-81.
87. Murphy E, FitzGerald O, Saxne T, Bresnihan B. Increased serum cartilage oligomeric matrix protein levels and decreased patellar bone mineral density in patients with chondromalacia patellae. *Ann Rheum Dis* 2002;61:981-5.
88. Andersson ML, Thorstensson CA, Roos EM, Petersson IF, Heinegård D, Saxne T. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. *BMC Musculoskelet Disord* 2006;7:98.
89. Andersson ML, Petersson IF, Karlsson KE, Jonsson EN, Månsson B, Heinegård D, *et al.* Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. *Ann Rheum Dis* 2006;65:1490-4.
90. Bijlsma JW, Berenbaum F, Lefeber FP. Osteoarthritis: An update with relevance for clinical practice. *Lancet* 2011;377:2115-26.
91. Zhang J. Meta-analysis of serum C-reactive protein and cartilage oligomeric matrix protein levels as biomarkers for clinical knee osteoarthritis. *BMC Musculoskelet Disord* 2018;19:22.
92. Hamodat ZM, Al-Ashou LK. Study of cartilage oligomeric matrix protein (COMP) level in serum and synovial fluid for osteoarthritis patients and its relationship level of Vitamin D, parathyroid hormone and disease severity. *Ann Trop Med Public Health* 2020.
93. Verma P, Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: A novel diagnostic and prognostic biomarker. *J Orthop Res* 2013;31:999-1006.
94. Singh S, Kumar D, Kumar S, Sharma N. Cartilage oligomeric matrix protein (COMP) and hyaluronic acid (HA): Diagnostic biomarkers of knee osteoarthritis. *MOJ Orthop Rheumatol* 2015;2:00044.